Ki-67 may be useful in differentiating between keratoacanthoma and cutaneous squamous cell carcinoma

Clinical and Experimental Dermatology

Volumn 39, Issue 2, 2014, Pages 216-218

  Scola, N ^a   Segert, H M ^a   Stucker M ^a   Altmeyer, P ^a   Gambichler, T ^a   Kreuter, A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATOACANTHOMA; KI-67 ANTIGEN; PROLIFERATING CELL NUCLEAR ANTIGEN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894218708     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/ced.12219     Document Type: Letter

References (5)

1. Hiraiwa A, Fujita M, Adachi A, et al,. Specific distribution patterns of hCDC47 expression in cutaneous diseases. J Cutan Pathol 1998; 25: 285-90.
2. Ota T, Clayton AC, Minot DM, et al,. Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol 2011; 24: 277-87.
3. Brown DC, Gatter KC,. Ki67 protein: the immaculate deception? Histopathology 2002; 40: 2-11.
4. Ribeiro D, Narikawa S, Marques ME,. Expression of apoptotic and cell proliferation regulatory proteins in keratoacanthomas and squamous cell carcinomas of the skin. Pathol Res Pract 2008; 204: 97-104.
5. Shimizu T, Muto M, Murakami T, et al,. Overexpression of p53 protein associated with proliferative activity as evaluated by Ki-67 immunostaining in well-differentiated squamous cell carcinoma of the skin. Dermatology 1997; 195: 224-7.